Fenfluramine for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 May 2024
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 [ID5104]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 May 2024
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 October 2024
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: 13 November 2024
Digitally enabled therapy for chronic tic disorders and Tourette Syndrome in children and young peopleStatus:In developmentProgramme:Medical technologies guidanceExpected publication date: 19 December 2024
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 24 April 2024Expected publication date: TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC